KOL Insight

2014 October Dermatology Survey

We performed a 5-question survey of 21 dermatologists to gauge usage of drugs and devices for the treatment of common dermatological conditions and for aesthetic procedures.

October 30, 2014

2015 Breast Cancer Pulse #1

This five-question survey of oncologists focuses on treatments for metastatic or locally advanced, HR+/HER2- breast cancer.

May 13, 2015

2015 Breast Cancer Pulse #2

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.

May 26, 2015

2015 Breast Cancer Pulse #3

We performed a 5-question survey of 25 oncologists in the US to gauge current prescribing practices for breast cancer treatments.

June 12, 2015

2015 Cancer Drug Pricing Surveys

$799.00

We performed two 5-question surveys of oncologists in the US to gauge the impact of cancer treatment costs on prescribed therapies.

August 10, 2015

2015 Chronic Lymphocytic Leukemia (CLL) KOL Interview

Following our live coverage of ASH, we interviewed a KOL who specializes in treating lymphoid malignancies to provide further insight on current and future paradigms for the treatment of CLL and NHLs.

January 28, 2015

2015-cll-pulse-2-drug-usage-and-reimbursement

2015 Chronic Lymphocytic Leukemia (CLL) Pulse

We performed a 5-question survey of 40 hematology-oncology specialists in the US to gauge current prescribing practices and physician experience with reimbursement for ibrutinib and idelalisib for the treatment of patients with CLL.

January 27, 2015

2015 Jardiance EMPA-REG CVOT Pulse

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).

November 1, 2015

2015 PCSK9 Inhibitors Pulse

Following the approval of the first PCSK9 Inhibitor, Praluent (SNY, REGN), this 5- question survey of 23 cardiologists evaluated attitudes towards the class, projected usage prior to their CVOTs depending on insurance prior authorization, preference of Praluent vs Repatha (AMGN), and how the oral CETP inhibitors would impact PCSK9 usage under different outcomes study scenarios.

August 19, 2015

2015 Post-AAIC KOL Interview

Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.

August 1, 2015

2016 Biomedtracker ASCO Survey

Biomedtracker performed a 5-question survey of 39 United States and European (France, Germany, Italy, and United Kingdom) oncologists after the American Society of Clinical Oncology (ASCO) meeting to gauge interest in new data presented on drugs in clinical development.

June 8, 2016

2016 Biomedtracker Post-EASL Hepatitis C Survey

We performed a 9-question survey of 29 EU and 31 US hepatologists and gastroenterologists after the European Association of the Study of the Liver (EASL) International Liver Conference (ILC) from April, 2016 in Barcelona to gauge current and projected prescribing practices for hepatitis C virus (HCV) infection.

May 16, 2016

2018 ASH Pulse Survey

This 9-question pulse survey of 102 hematologic oncologists practicing throughout the United States and Europe.

January 2, 2019

2019 ASH Pulse Survey

This 8-question Pulse survey of 55 hematologic oncologists practicing throughout the United States and Europe asks respondents their thoughts on several topics presented at the 2019 American Society of Hematology (ASH) Annual Meeting. Survey questions and additional resources are listed further below.

January 10, 2020

Abuse-Deterrent Opioids Survey KOL Interview

Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

March 9, 2017

Acne Prescribing Practices Pulse Survey

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.

November 29, 2016

Acute Lymphocytic Leukemia KOL Interview

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

February 9, 2016

Datamonitor-Acute-Myelogenous-Leukemia-KOL-Interview

Acute Myelogenous Leukemia (AML) KOL Interview

Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.

August 19, 2016

Acute Myeloid Leukemia (AML) KOL Interview – Italy

An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.

March 14, 2022

Acute Myeloid Leukemia (AML) KOL Interview – UK

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include ASTX727, guadecitabine, idasanutlin, Iomab-B, oral azacitidine, pevonedistat, and Zeltherva.

April 1, 2020

Acute Myeloid Leukemia (AML) KOL Interview – UK

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

Acute Myeloid Leukemia (AML) KOL Interview – US, East Coast

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

April 1, 2020

Acute Myeloid Leukemia (AML) KOL Interview – US, South

A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

March 14, 2022

ADPD Alzheimer’s Disease Pulse

Overview We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification. Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).

March 19, 2015

Alzheimer’s Disease KOL Interview – UK

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.

January 20, 2019

Alzheimer’s Disease KOL Interview – US, Northeast

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Alzheimer’s Disease KOL Interview – US, South

This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

January 28, 2019

Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.

October 21, 2015

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

Anemia in Chronic Kidney Disease KOL Interview – US, West Coast

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Midwest

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

Aromatase Resistance and Palbociclib for Breast Cancer

$89.00

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.

April 1, 2014

Asthma and COPD KOL Interview

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

February 29, 2016

Atopic Dermatitis and Psoriasis KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Atopic Dermatitis and Psoriasis KOL Interview – US, South

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Biomedtracker Diabetic Nephropathy/Diabetic Kidney Disease KOL Interview

Biomedtracker interviewed a nephrologist based in the US Midwest to determine his views on the drugs in development for diabetic nephropathy/diabetic kidney disease.

May 13, 2016

Biomedtracker Entresto Pulse

Uptake of Entresto (NVS) in the US has been slow following approval in July 2015. Part of that is due to the time it has taken to secure insurance coverage, but physicians have complained about other insurance barriers, as well, and there are also clinical factors that could play a role.

May 11, 2016

Biomedtracker Q3 2017 Outlook Report

In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

August 2, 2017

Biosimilars and Reimbursement KOL Interview

Topics: Biosimilars and Reimbursement

Physician Information

Specialty: Specialty Pharmaceuticals

Location: Alexandria, VA

July 31, 2015

Bladder Cancer KOL Interview – US

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

May 31, 2019

Breast Cancer KOL Insight Interview

Physicians are starting to use Perjeta (Roche) as an add-on to Herceptin in the adjuvant setting due to a recent
change in NCCN (National Comprehensive Cancer Network, an alliance of major cancer centers) guidelines.

May 8, 2014

Breast Cancer Pulse #1

We performed a 5-question survey of 22 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs discussed: •Ibrance (palbociclib, PFE) •Afinitor (everolimus, NVS) •Halaven (eribulin, Eisai) •Abraxane (nab-paclitaxel, CELG) •Doxil (pegylated liposomal doxorubicin, JNJ) •Gemzar (gemcitabine, LLY) •Xeloda (capecitabine, Roche)

October 31, 2016